Herein, we propose an innovative methodology for concurrent quantification of quercetin (QRN), letrozole (LTZ) and bicalutamide (BTM) anti- breast cancer combination. This study introduces the first DES-based microextraction method for the simultaneous quantification of this anti-cancer drug combination. Prior to HPLC-PDA separation, a hydrophobic natural DES was utilized as an extractant in dispersive liquid- liquid microextraction (DLLM). Furthermore, to ensure robustness and reliability, a quality-by-design (QbD) framework was implemented to systematically optimize the key approach parameters. The optimal parameters for extraction were 100 μL of DES and vortexing for 20 s without any buffer or salt addition. The evolved approach was validated adhering to International Conference on Harmonization (ICH) guidelines, exhibiting a good linear correlation over a concentration range of 0.03–30 μg/mL for QRN and 0.05–30 μg/mL for LTZ and BTM. The established approach was then employed to analyze the target medicines in pharmaceutical preparations, environmental water and human plasma achieving recovery rates exceeding 97 %. Finally, a comprehensive sustainability assessment was conducted using twelve metrics, evaluating factors such as innovation, practicality, environmental friendliness, analytical performance, overall efficiency, whiteness, and solvent sustainability. Pairing QbD and DES-LLME provides significant progress in the analysis of the studied drugs and offers prospective potential in clinical and pharmacological research, improving patient care and therapeutic results.
扫码关注我们
求助内容:
应助结果提醒方式:
